MAY 13, 2016 6:11 AM PDT

C9ORF72 Repeat Expansion Impairs Protein Degradation in FTD/ALS

WRITTEN BY: Cassidy Reich
Alzheimer’s disease gets most of the press for neurodegeneration, but it is not the only devastating neurodegenerative disease out there. Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are both less prevalent than Alzheimer’s, but they present their own issues and challenges. ALS affects ~30,000 people in the U.S. and is relatively fast-moving, with an average life expectancy from time of diagnosis of 2-5 years. FTD is slightly more prevalent, affecting ~50,000-60,000 in the U.S. What is interesting about FTD is that the average age of diagnosis is 57, a full 13 years earlier than the average age of Alzheimer’s diagnosis. ALS is characterized by the degeneration of motor neurons and FTD is more cognitive and behavioral deficits, but there is some evidence that these two diseases share an underlying pathology, specifically the G4C2 repeat expansions in C9ORF72.
 

ALS and FTD that are caused by these repeat expansions are collectively referred to as c9FTD/ALS. This repeat expansion can be transcribed into sense and antisense mRNA which is then translated to produce a series of proteins of repeating dipeptides. Using the single letter code for amino acids, these dipeptides are GP, GA, GR, PA, and PR. Researchers at the Mayo Clinic Department of Neuroscience were especially interested in the role the poly(GA) peptides play in disease pathogenesis.

In the brains of patients with c9FTD/ALS, there are abundant poly(GA) inclusions in the cytoplasm of neurons. Applying poly(GA) to cultured cells or primary neurons induced toxicity, lending validity to their theory that poly(GA) aggregates have a strong contribution in c9FTD/ALS disease pathology. To study the mechanisms behind poly(GA)’s pathological role in c9FTD/ALS, the researchers used a mouse model that specifically looks at poly(GA) with no other pathologies. To create this mouse model, they used an adeno-associated viral (AAV) vector to express poly(GA) in the mouse central nervous system. They also wanted to specifically look at the pathological role of aggregated poly(GA), so they created a poly(GA) mutant [poly(GA)mut] that is incapable of aggregating. The poly(GA)-expressing mice had a very strong neurodegeneration phenotype, with abundant poly(GA) inclusions; neuronal loss in the cortex, hippocampus, and cerebellum; and behavioral, motor, and memory deficits. The poly(GA)mut mice had none of these signs of neurodegeneration, suggesting that poly(GA) pathology is dependent on poly(GA) aggregation.
 
Visible inclusions in neurons from the poly(GA) mice.

The most important finding from this paper though is the discovery that poly(GA) aggregation leads to HR23 pathology. HR23A and HR23B are proteins that are involved in DNA repair and in shuttling proteins that are marked for degradation with ubiquitin to the proteasome. The researchers saw that ubiquitinated proteins and HR23 proteins accumulate in poly(GA) inclusions. The model they propose is that poly(GA) aggregates sequester HR23 proteins, leading to an accumulation of ubiquitinated proteins in the cytoplasm. Have a build-up of proteins that need to be degraded is very cytotoxic.

This paper is extraordinarily detailed and I have barely scratched the surface of the experiments that the researchers did. The main takeaway is that poly(GA) aggregation contributes significantly to c9FTD/ALS neurodegeneration by initiating HR23 pathology and impairing the ubiquitin-proteasome system. It also hints at the possibility of targeting the poly(GA) monomers to inhibit their aggregation as a therapeutic strategy. That kind of therapy is a long way away, but research like this is the first step.  

Sources: Nature Neuroscience, ALS, and FTD
About the Author
  • Cassidy is a curious person, and her curiosity has led her to pursue a PhD in Pharmacology at the New York University Sackler Institute of Biomedical Sciences. She likes to talk about science way too much, so now she's going to try writing about it.
You May Also Like
DEC 22, 2019
Drug Discovery & Development
DEC 22, 2019
Effective Therapeutic Approved for Migraines
The U.S Food and Drug Administration has now approved a new medication for migraines. The drug is called ‘ubrogepant (Ubrelvy)’ and comes in th...
DEC 27, 2019
Drug Discovery & Development
DEC 27, 2019
Acne Drug Linked to 10 Suicides
UK regulators claim to have found a link between at least ten suicides and a powerful acne drug, manufactured under the names Roaccutane and Accutane. Alth...
JAN 08, 2020
Clinical & Molecular DX
JAN 08, 2020
MicroRNA emerges as a biomarker for migraines
Intense, debilitating pain that can last for days. Nausea, numbness and sensitivity to light. For people who experience migraines, it’s frustrating t...
JAN 03, 2020
Neuroscience
JAN 03, 2020
Natural Smells Effective in Reducing Stress Levels
For some time now, studies have been abound on the benefits of nature for both physical and mental health. Now, however, research shows that smells derived...
JAN 07, 2020
Cell & Molecular Biology
JAN 07, 2020
Cancer-Like Metabolism Can Fuel Brain Growth
During evolution, the size of the human brain increased significantly compared to other primates....
JAN 17, 2020
Neuroscience
JAN 17, 2020
Fewer Connections Between Brain Cells for Schizophrenia
Approximately 1% of the world’s population have schizophrenia, with 3.2 million Americans having the disorder. Now, for the first time, advanced brai...
Loading Comments...